Académique Documents
Professionnel Documents
Culture Documents
STUDY PROTOCOL
Open Access
Abstract
Background: Treatment guidelines recommend watchful waiting for children older than 2 years with acute otitis
media (AOM) without perforation, unless they are at high risk of complications. The high prevalence of chronic
suppurative otitis media (CSOM) in remote Aboriginal and Torres Strait Islander communities leads these children
to be classified as high risk. Urban Aboriginal and Torres Strait Islander children are at lower risk of complications,
but evidence to support the subsequent recommendation for watchful waiting in this population is lacking.
Methods/Design: This non-inferiority multi-centre randomised controlled trial will determine whether watchful
waiting is non-inferior to immediate antibiotics for urban Aboriginal and Torres Strait Islander children with AOM
without perforation. Children aged 2 16 years with AOM who are considered at low risk for complications will be
recruited from six participating urban primary health care services across Australia. We will obtain informed consent
from each participant or their guardian. The primary outcome is clinical resolution on day 7 (no pain, no fever of at
least 38 C, no bulging eardrum and no complications of AOM such as perforation or mastoiditis) as assessed by
general practitioners or nurse practitioners. Participants and outcome assessors will not be blinded to treatment.
With a sample size of 198 children in each arm, we have 80 % power to detect a non-inferiority margin of up to
10 % at a significance level of 5 %, assuming clinical improvement of at least 80 % in both groups. Allowing for a
20 % dropout rate, we aim to recruit 495 children.
We will analyse both by intention-to-treat and per protocol. We will assess the cost- effectiveness of watchful
waiting compared to immediate antibiotic prescription. We will also report on the implementation of the trial from
the perspectives of parents/carers, health professionals and researchers.
(Continued on next page)
* Correspondence: p.abbott@westernsydney.edu.au
1
School of Medicine, Western Sydney University, Sydney, NSW, Australia
Full list of author information is available at the end of the article
2016 Abbott et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Page 2 of 10
Discussion: The trial will provide evidence for the safety and effectiveness of watchful waiting for the management
of AOM in Aboriginal and Torres Strait Islander children living in urban settings who are considered to be at low
risk of complications.
Trial registration: The trial is registered with Australia New Zealand Clinical Trials Registry (ACTRN12613001068752).
Date of registration: 24 September 2013.
Keywords: Otitis media, Acute otitis media, Aboriginal and Torres Strait Islander peoples, Indigenous population,
Children, Antimicrobial agents, Randomised controlled trial
Background
Acute otitis media (AOM) is a common reason for
childhood presentation to health services and for prescription of antibiotics [1] and is commonly managed in
general practice in Australia [2]. AOM creates a large
health and cost burden for individuals and communities
[1, 3]. Otitis media (OM) refers to inflammation of the
middle ear space, which is characterised by the presence
of middle ear effusion and causes illness and hearing loss
[1]. In AOM there are also symptoms and signs of acute
infection [4]. Serious complications of AOM, such as
chronic suppurative otitis media (CSOM) (persistent ear
discharge through a perforation in the eardrum) and
mastoiditis, are rare in developed countries, where most
cases of AOM resolve spontaneously [1, 5].
Antibiotics are not recommended for most children in
developed countries with AOM due to limited clinical
benefit [4] and the personal and public health risks of
antibiotic resistance [68]. Aboriginal and Torres Strait
Islander children who live in remote communities,
where the incidence of AOM and prevalence of CSOM
are high, are among those who are to expected benefit
from antibiotic treatment for AOM [911]. However,
there is little evidence for the appropriate management
of AOM in the majority of Aboriginal and Torres Strait
Islander children who live in urban settings and who are
considered to be at lower risk of complications.
Diagnosis and management of AOM
Page 3 of 10
Design
Study aims
Methods/Design
Primary objective
Study setting
Page 4 of 10
Intervention/Comparison
Page 5 of 10
Page 6 of 10
Assessment
Performed by
Day 0
Day 3
Day 7
Day 14
Week 7 3 months
GP/NP
Temperature
GP/NP/Health service
RO or AI
Tympanometry
GP/NP/AMS Health
service RO or/AMS AI
Digital video-otoscopy
GP/NP/Health service
RO or AI
Symptoms questionnaire
Progress questions
Serious adverse events/severe studyrelated adverse events
AI associate investigator, AMS Aboriginal Medical Service, GP general practitioner, NP nurse practitioner, RO research officer
a
Bracketed day/week numbers in the Post-randomisation column above represent acceptable time ranges.
With 198 children in each arm of the study, the study will
have 80 % power to detect a non-inferiority margin of up to
10 % at a significance level of 5 %, assuming a clinical
improvement rate of at least 80 % in both study groups
[38]. Allowing for a dropout rate of up to 20 % at days
5 10, the total sample size required is 495 children.
Analysis
include both unadjusted (crude) and adjusted ORs. Adjusted ORs will be obtained using multivariable logistic
regression, adjusting for baseline covariates. Time to
resolution of AOM symptoms will be modelled using a
multilevel Cox (proportional hazards) regression analysis
and graphically displayed using Kaplan-Meier curves.
Secondary analyses by stratification factors (recruitment
site and age) will be carried out, numbers permitting.
Page 7 of 10
As a secondary outcome measure, we will assess the costeffectiveness of watchful waiting compared to immediate
antibiotic prescription, as measured through the incremental cost-effectiveness ratio (ICER). The ICER is defined as:
}ICER} C2 C1 = Q2 Q1
where Ci and Qi denote costs and Quality-adjusted Life
Years (QALYs) [40] associated with the treatment received
in trial arm i, and i is 1 for antibiotic treatment and 2 for
watchful waiting.
Costs of treatment
Discussion
The WATCH trial will answer the important clinical question: whether watchful waiting is (or is not) inferior to immediate antibiotic therapy for urban Aboriginal children
with AOM who are at low risk of complications. We will
assess the cost-effectiveness of the two approaches and
qualitatively examine the acceptability of the alternate approaches to management of AOM to parents and carers,
and health care providers. Furthermore, we will examine
experiences of the trial process itself in order to inform future RCT studies in Aboriginal health settings.
This trial will make an important contribution to the
evidence base for the safe management of AOM in
urban Aboriginal children. Australian guidelines for the
management of AOM have recently been updated [5]
and Aboriginal and Torres Strait Islander children living
in urban settings are no longer classified as high risk for
complications of AOM, and thus health care providers
are advised they should be treated with watchful waiting.
This requires a change in clinical practice. The expert
consensus guideline advice has been extrapolated from
studies in low-risk, developed countries internationally.
There have been no studies into the relative effectiveness
of a watchful waiting approach for urban Aboriginal and
Torres Strait Islander children, nor of attitudes of carers
and health care providers to this approach.
Research undertaken with Aboriginal and Torres Strait
Islander people must have net benefits for communities,
incorporate community research control, be conducted
in a manner sensitive to the cultural principles of Aboriginal society, be appropriately resourced and enhance
the skills and knowledge of the Aboriginal and Torres
Strait Islander people, communities and organisations
that are participating in the project [34]. This study has
been designed with awareness and commitment to these
guiding principles and to the flexibility required to
undertake a randomised controlled trial in Aboriginal
and Torres Strait Islander health settings.
Ear health is a core priority for Aboriginal communities and the health care providers who work with those
communities. Aboriginal and Torres Strait Islander
people experience marked disadvantage compared to
other Australians [45] and effective treatment of ear
disease and prevention of hearing impairment in Aboriginal children is vital to maximise health and learning
outcomes [22]. The ultimate goal of this research is to
ensure appropriate treatment of acute infections of the
middle ear so as to maintain the ear health of Aboriginal
children and decrease their risk of developing chronic
complications.
Page 8 of 10
Trial status
Page 9 of 10
15.
16.
17.
Author details
1
School of Medicine, Western Sydney University, Sydney, NSW, Australia.
2
University of Sydney, Sydney, NSW, Australia. 3Menzies School of Health
Research, Darwin, NT, Australia. 4Discipline of General Practice, University of
Queensland, Brisbane, QLD, Australia. 5Southern Queensland Centre of
Excellence in Aboriginal and Torres Strait Islander Primary Health Care (Inala
Indigenous Health Service), Queensland Health, Brisbane, QLD, Australia.
6
University of Newcastle, Newcastle, NSW, Australia. 7Indigenous Studies
Research Network, Queensland University of Technology, Brisbane, QLD,
Australia. 8Centre for Big Data Research in Health, University of NSW, Sydney,
NSW, Australia. 9Sydney Medical School Westmead, University of Sydney,
Sydney, NSW, Australia. 10Awabakal Aboriginal Primary Health Care Centre,
Newcastle, NSW, Australia. 11Winnunga Nimmityjah Aboriginal Health Service,
Canberra, ACT, Australia. 12Aboriginal and Torres Strait Islander Community
Health Services, Brisbane, QLD, Australia. 13Tharawal Aboriginal Corporation,
Sydney, NSW, Australia.
Received: 12 December 2015 Accepted: 20 February 2016
18.
19.
20.
21.
22.
23.
24.
References
1. Grevers G, First International Roundtable ENT Meeting Group. Challenges in
reducing the burden of otitis media disease: an ENT perspective on improving
management and prospects for prevention. Int J Pediatr Otorhinolaryngol.
2010;74(6):5727.
2. Charles J, Pan Y, Britt H. Trends in childhood illness and treatment in
Australian general practice, 19712001. Med J Aust. 2004;180(5):2169.
3. Taylor PS, Faeth I, Marks MK, Del Mar CB, Skull SA, Pezzullo ML, et al. Cost of
treating otitis media in Australia. Expert Rev Pharmacoecon Outcomes Res.
2009;9(2):13341.
4. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson
MA, et al. The diagnosis and management of acute otitis media. Pediatrics.
2013;131(3):e964e99.
5. Darwin Otitis Guidelines Group & Office for Aboriginal and Torres Strait
Islander Health Otitis Media Technical Advisory Group. Recommendations
for clinical care guidelines on the management of otitis media in Aboriginal &
Torres Strait Islander populations. Canberra: Commonwealth of Australia; 2010.
6. Gottlieb T, Nimmo GR. Antibiotic resistance is an emerging threat to public
health: an urgent call to action at the Antimicrobial Resistance Summit
2011. Med J Aust. 2011;194(6):2813.
7. Pingault NM, Bowman JM, Lehmann D, Riley TV. Antimicrobial susceptibility
of Moraxella catarrhalis isolated from children in Kalgoorlie-Boulder, Western
Australia. Pathology. 2010;42(3):2739.
8. Costelloe C, Metcalfe C, Lovering A, Mant D. Hay AD. Effect of antibiotic
prescribing in primary care on antimicrobial resistance in individual patients:
systematic review and meta-analysis. BMJl. 2010;340:c2096.
9. Morris PS. A systematic review of clinical research addressing the
prevalence, aetiology, diagnosis, prognosis and therapy of otitis media in
Australian Aboriginal children. J Paediatr Child Health. 1998;34(6):48797.
10. OConnor TE, Perry CF, Lannigan FJ. Complications of otitis media in
Indigenous and non-Indigenous children. Med J Aust. 2009;191(9 Suppl):S604.
11. Leach AJ, Morris PS, Mathews JD. Compared to placebo, long-term
antibiotics resolve otitis media with effusion (OME) and prevent acute otitis
media with perforation (AOMwiP) in a high-risk population: a randomized
controlled trial. BMC Paediatrics. 2008;8:23.
12. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux
RA, et al. Antibiotics for acute otitis media: a meta-analysis with individual
patient data. Lancet. 2006;368(9545):142935.
13. Spurling GK, Del Mar CB, Dooley L, Farley R. Delayed antibiotics for
respiratory infections. Cochrane Database Syst Rev. 2007;3:CD004417.
14. Takata GS, Chan LS, Shekelle P, Morton SC, Mason W, Marcy SM. Evidence
assessment of management of acute otitis media: I. The role of antibiotics
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
Page 10 of 10
BioMed Central publishes under the Creative Commons Attribution License (CCAL). Under
the CCAL, authors retain copyright to the article but users are allowed to download, reprint,
distribute and /or copy articles in BioMed Central journals, as long as the original work is
properly cited.